Moderna

Moderna

Organization

Heard in 237 episodes across 75 shows since Jan 2026

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It develops RNA therapeutics, especially mRNA vaccines, using messenger RNA to instruct cells to produce proteins that can generate immune responses; its pipeline also includes programs targeting infectious diseases and cancer.

Discussed inMarkets66%Business18%Politics7%AI & Tech4%

Episodes

237
across 75 shows

This week

0
episodes on 0 shows

Expert statements

111
72 positive · 29 negative

Share of the conversation

Mentions of Moderna per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.

0.0‰0.5‰1‰1.5‰Aug 24Sep 15Oct 8Oct 30Nov 21
Show the data
DayShare (7-day)Mentions
Oct 100.17‰1
Oct 120.19‰4
Oct 130.16‰3
Oct 140.15‰2
Oct 150.15‰3
Oct 160.14‰3
Oct 170.15‰2
Oct 180.16‰2
Oct 190.14‰1
Oct 200.13‰2
Oct 210.14‰3
Oct 220.12‰2
Oct 230.21‰14
Oct 250.19‰1
Oct 260.21‰3
Oct 270.22‰3
Oct 280.21‰2
Oct 290.20‰1
Oct 300.13‰6
Oct 310.16‰3
Nov 30.11‰1
Nov 40.11‰2
Nov 50.11‰1
Nov 60.09‰4
Nov 130.02‰2
Nov 160.05‰4
Nov 170.08‰4
Nov 190.10‰2
Nov 200.10‰2
Nov 210.10‰1

The full trend: rank, tone and why it is trending →

Email alert

Email me when Moderna comes up on a podcast

One email a week at most, with the new episodes that mention Moderna. Free, no account needed, unsubscribe in one click.

What experts have said about Moderna

111 statements · 72 positive · 29 negative · 4 mixed · 6 neutral

  1. Tierney BaumPositiveNov 17, 2026· BioCentury This Week

    Moderna and Merck’s neoantigen program leads the pipeline with the most Phase 3 trials.

    “they're still clearly ahead in the pipeline. They have the most phase three trials.”

    Listen at 12:23

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  2. Tierney BaumNeutralNov 17, 2026· BioCentury This Week

    The Moderna and Merck program’s primary readout is not expected until 2028.

    “this one's still not going to reach its primary readout till 2028.”

    Listen at 12:30

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  3. Jim CramerPositiveNov 13, 2026· Mad Money w/ Jim Cramer

    Moderna’s stock rose from $63 to above $174 in one day.

    “Moderna was a $63 stock. The next day, it closed above $174”

    Listen at 28:10

    Open the episode · NVIDIA Without Jensen, Anthropic IPO Risks & Moderna’s Cancer Vaccine 11/12/26

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

237 episodes featuring Moderna, newest first